Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an update.
CanSino Biologics Inc. announced a supplemental update regarding its 2025 H Share Option Scheme, clarifying that the grant of H Share Options is contingent upon the scheme’s approval by shareholders at an upcoming Extraordinary General Meeting (EGM). The company plans to distribute a circular with more details about the scheme and the EGM notice to shareholders soon, which could impact the company’s stock option framework and shareholder engagement.
The most recent analyst rating on (HK:6185) stock is a Buy with a HK$66.60 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily engaged in the research, development, and commercialization of vaccine products. The company focuses on providing innovative vaccines to address global health challenges.
Average Trading Volume: 2,321,577
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.4B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.